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 1 
ABSTRACT 20 
Picornaviruses are the most commonly encountered infectious agents in mankind. 21 
They typically cause mild infections of the gastrointestinal or respiratory tract, but 22 
sometimes also invade the central nervous system. There, they can cause severe 23 
diseases with long-term sequelae and even be lethal. The most famous picornavirus is 24 
polio that was a huge burden for mankind for a long time. A successful vaccination 25 
campaign brought polio close to eradication, but neurological diseases caused by 26 
other picornaviruses have been increasingly reported since the late 1990s. In this 27 
review we focus on enterovirus 71, coxsackievirus A16, enterovirus 68 and human 28 
parechovirus 3 that have recently drawn attention because of their links to severe 29 
neurological diseases. We discuss the clinical relevance of these viruses, the primary 30 
role of humoral immunity to control them and summarize current knowledge on 31 
neutralization of such viruses by antibodies.32 
 2 
INTRODUCTION 33 
Picornaviridae is one of the largest viral families. According to the International 34 
Committee on Taxonomy of Viruses (ICTV) it contains 31 genera that together 35 
enclose 54 viral species (Adams et al., 2015). They infect diverse hosts, from lower 36 
vertebrates to mammals. The genera Kobuvirus, Salivirus, Cosavirus, Cardiovirus, 37 
Hepatovirus, Parechovirus, and Enterovirus infect humans (Fig. 1) (Tapparel et al., 38 
2013).   39 
Hepatovirus A, Parechovirus A and multiple enterovirus genera can cause 40 
symptomatic infections in humans. They typically result in mild disease of 41 
gastrointestinal or respiratory tract, but sometimes are associated with severe 42 
conditions. For instance, coxsackievirus B (CVB) type 3 has an established role in 43 
viral myocarditis (Fairweather et al., 2012), and CVB4 is well-documented as a viral 44 
trigger of type 1 diabetes onset (Yeung et al., 2011).  45 
Several human picornaviruses can target the central nervous system (CNS) 46 
and cause severe neurological diseases. The most well known of them is polio (PV). It 47 
caused outbreaks of flaccid paralytic disease in children and was a health care burden 48 
for a long time, until development of vaccines and a worldwide vaccination campaign 49 
brought it close to eradication (Morales et al., 2016). However, other neurotropic 50 
picornaviruses still have potential to cause outbreaks of neurological diseases, such as 51 
severe and life-threatening meningoencephalitis, encephalitis or acute flaccid 52 
paralysis (AFP). A recent metagenomic study identified members of Cosavirus, 53 
Cardiovirus, Kobuvirus, Enterovirus and Parechovirus genera in clinical samples 54 
from AFP children (Victoria et al., 2009). This study corroborated epidemiological 55 
and experimental work that has already established firm connections between 56 
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Enterovirus and Parechovirus and neurological diseases in humans and is described 57 
below in detail.  58 
 59 
PICORNAVIRUS CNS TARGETING 60 
Picornaviruses spread via the fecal-oral or respiratory routes, and the primary sites of 61 
their replication are the gastrointestinal or respiratory tracts. Nevertheless, at least 62 
some enteroviruses (EV) and human parechoviruses (HPeV) are routinely neurotropic 63 
(Rhoades et al., 2011; Wiley et al., 2015).  64 
Picornaviruses utilize a variety of widely expressed molecules as their entry 65 
receptors (Evans & Almond, 1998). Such receptors are often present on the surface of 66 
cells within the CNS. For example, a receptor for PV—CD155—is expressed in the 67 
motor neurons of the spinal cord anterior horns, which are affected during 68 
poliomyelitis (Gromeier et al., 2000). Human scavenger receptor class B member 2 69 
(hSCARB2) that is utilized by EV71 and CVA16, is expressed on a variety of cells, 70 
including neurons and glial cells (Jiao et al., 2014). Thus, the CNS cells are 71 
susceptible for infection. In addition, the nervous tissue has reduced immune 72 
surveillance and weaker interferon (IFN) responses, and is a plausible site for 73 
replication of IFN-sensitive picornaviruses (Ida-hosonuma et al., 2005). Hence, the 74 
CNS cells are also permissive for viral replication. 75 
There is molecular evidence suggesting that picornaviruses can invade the 76 
CNS by three possible mechanisms: peripheral nerve infection, blood-brain barrier 77 
crossing and “Trojan horse” invasion.  78 
The first mechanism is peripheral nerve infection followed by retrograde 79 
axonal transport and trans-synaptic spread in nervous tissue (Fig. 2 (a) and (b)). The 80 
evidence for this came from tissue culture studies and in vivo experimental models for 81 
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PV and also from EV71 patient material (Chen et al., 2007; Daley et al., 2005; Ren & 82 
Racaniello, 1992; Wong et al., 2008).  83 
The second mechanism proposes that during viremia viruses cross the blood-84 
brain barrier (BBB) and infect neural cells. Indeed, high levels of viremia and 85 
inflammation can decrease tight junction protein expression, disrupt BBB integrity 86 
and facilitate viral invasion (Fig. 2 (c)) (Chai et al., 2014; Daniels et al., 2014). 87 
Although the inflammation-induced BBB breakdown has not been directly shown for 88 
picornaviruses, their prolonged viremia correlates with severe CNS infections and 89 
supports this possibility (Cheng et al., 2014). Picornaviruses can also cross the BBB 90 
in an active manner: PV can move through the BBB at a rate comparable to a BBB-91 
crossing antibody (Fig. 2 (d)) (Yang et al., 1997). Such trafficking happens 92 
independently of the PvR and appears to rely on transferrin receptor 1 (Mizutani et 93 
al., 2016).  94 
The third mechanism of neurotropism involves migration of infected cells, 95 
such as dendritic cells, monocytes, macrophages, T- and B-cells and nestin+ myeloid 96 
cells to the CNS, and is called a “Trojan horse” invasion (Fig. 2 (e)) (Tabor-Godwin 97 
et al., 2010; Vuorinen et al., 1996; Wahid et al., 2005).  98 
Neurotropic picornaviruses often target different regions of the CNS, and 99 
hence vary in their clinical manifestations. Infection of meningeal cells or cells of the 100 
ventricular lining results in aseptic meningitis—a non-bacterial inflammation of 101 
tissues lining the brain (Irani, 2008). Infection of neurons with subsequent 102 
inflammation of brain parenchyma results in encephalitis that can have long-term 103 
sequelae or be fatal (Verboon-Maciolek et al., 2008). Inflammation of the spinal cord 104 
grey matter results in myelitis and can lead to limb paralysis (Irani, 2008). All these 105 
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conditions can be caused by different picornaviruses and their incidences are highest 106 
in children (Nicolosi et al., 1986). 107 
NEUROTROPIC PICORNAVIRUSES IN FOCUS 108 
Confirmed neurotropic picornaviruses are members of Enterovirus and Parechovirus 109 
genera. The genus Enterovirus includes many recognized pathogens, such as PV, 110 
CVA, coxsackieviruses B (CVB), rhinoviruses and EV, whereas genus Parechovirus 111 
is smaller and includes one human pathogenic species—Parechovirus A. The 112 
infections are common, and in the US alone over 10 million symptomatic EV cases 113 
are reported annually (Strikas et al., 1986). Human EV and HPeV can be responsible 114 
for about 80% of aseptic meningitis cases (Esposito et al., 2014) and 11% of reported 115 
encephalitis cases (Koskiniemi et al., 2001).  Several types of EV can trigger myelitis 116 
with limb paralysis (Kincaid & Lipton, 2006).  117 
Not all serotypes of EV and HPeV cause CNS diseases. Enteroviruses 118 
associated with CNS infections include PV types 1, 2 and 3, echovirus types 9, 11, 30 119 
and 33, CVA type 16, CVB types 3 and 5 (Mistchenko et al., 2006), EV types 68 120 
(Messacar et al., 2015) and 71 (McMinn et al., 2001). Parechovirus CNS infections 121 
are almost exclusively caused by HPeV3 (Piralla et al., 2014).  In this review we will 122 
discuss EV71, CVA16, EV68 and HPeV3 that have gained attention due to their 123 
recent emergence and connection with CNS infections. 124 
 125 
Enterovirus 71 and Coxsackievirus A16 126 
EV71 was initially discovered as a CNS-targeting picornavirus: the first isolates came 127 
from two children with neurological symptoms in 1969 in California (Schmidt et al., 128 
1974). In 1973 it was identified as an etiological agent for hand-foot-and-mouth 129 
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disease (HFMD), a childhood exanthema characterized by rashes on the palms and 130 
soles, oral ulcers and brief febrile illness, but cases of aseptic meningitis were also 131 
observed (Hagiwara et al., 1978). In the middle of 1970s it caused a few small 132 
outbreaks of aseptic meningitis in the USA, Europe and Australia (Alexander et al., 133 
1994; Blomberg et al., 1974; Ishimaru et al., 1980; Kennett et al., 1974) and two 134 
rather large outbreaks of polio-like disease in Bulgaria and Hungary that affected 135 
predominantly infants with up to 21% of paralytic manifestations of which over a 136 
quarter were lethal (Chumakov et al., 1979; Nagy et al., 1982; Shindarov et al., 137 
1979).   138 
EV71 became a major health care threat in the late 1990s after a series of large 139 
outbreaks across the Asia-Pacific region. Most of the affected individuals were 140 
children; they often developed HFMD or herpangina, but upper respiratory tract 141 
infections (URTI) and non-specific rashes were occasionally observed. A fraction of 142 
EV71 infections had neurological and systemic manifestations, but, unlike earlier 143 
outbreaks when aseptic meningitis was the most frequent neurological manifestation, 144 
more recent outbreaks were characterized with the increased incidence of much more 145 
severe brainstem encephalitis and high mortality rate (Chan et al., 2000; Huang et al., 146 
1999). The first and largest outbreak in this series occurred in 1998 in Taiwan. 147 
Sentinel physicians reported almost 130,000 cases of HFMD, and over 400 cases of 148 
severe neurological involvement with almost 20% mortality rate (Ho et al., 1999b) 149 
and in total that outbreak affected about 1.5 million people (Solomon et al., 2010). In 150 
1999 an outbreak in Western Australia resulted in 6000 cases of HFMD and 29 cases 151 
of CNS disease, at least nine of which were severe and four developed long-term 152 
neurological sequelae (McMinn et al., 2001). EV71 outbreaks, most of which had 153 
lethal cases, continued in Korea, Singapore, Japan, Malaysia, Vietnam and Thailand 154 
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(Solomon et al., 2010). In 2008 there was a large EV71 outbreak in China with almost 155 
half a million reported HFMD cases and 122 fatal cases (Yang et al., 2009). The virus 156 
kept on circulating in China and contributed to HFMD cases with CNS complications 157 
and fatalities at least until 2014 (Liu et al., 2015a). By then, over 7.5 million cases of 158 
HFMD were reported in China alone, of which over 80,000 had neurological 159 
involvement and Chinese government declared the development of measures to 160 
control EV71 spread as a national priority (Liu et al., 2015b).  161 
Enterovirus 71 infections have been lately detected in Europe, including 162 
Denmark, France, Spain and the Netherlands, and although the incidence of EV71 163 
infections there is low, occasional lethal cases have already been reported (Cabrerizo 164 
et al., 2014; Fischer et al., 2014; van der Sanden et al., 2011; Schuffenecker et al., 165 
2011). Interestingly, German researchers have recently described a case of pediatric 166 
encephalitis caused by a novel EV71 genotype that likely arose from a recombination 167 
event (Karrasch et al., 2016). Although no epidemic activity of EV71 has so far been 168 
reported in Europe, the European Centre for Disease Prevention and Control (ECDC) 169 
risk assessment reported increased detections of EV71 in the first half of 2016 as 170 
compared to previous years, necessitating preparedness to control EV71 spread in 171 
Europe (ECDC, 2016).  172 
Importantly, EV71 often alternates or co-circulates with other Enterovirus A 173 
genotypes, mostly with CVA16, another recognized HFMD agent. Coxsackievirus 174 
A16 also predominantly infects children but, unlike EV71, typically causes milder 175 
symptoms and has much lower morbidity and mortality rate. In a comparative study 176 
of 177 EV71 and 64 CVA16 patients in Taiwan, only 6.3% of CVA16 infections 177 
developed aseptic meningitis, whereas 32% of EV71 cases resulted in aseptic 178 
meningitis, encephalitis, polio-like syndrome, encephalomyelitis and fatal pulmonary 179 
 8 
edema of which 7.9% were lethal (Chang et al., 1999). However, occasional severe 180 
and fatal CVA16 cases have been reported in USA (Wright et al., 1963), Taiwan 181 
(Wang et al., 2004), France (Legay et al., 2007), Japan (Goto et al., 2009), and China 182 
(Chen et al., 2015). 183 
The outbreaks of CVA16 were documented in Canada (1957) (Robinson et al., 184 
1958), Australia (1991) (Ferson & Bell, 1991), England and Wales (1994) (Bendig & 185 
Fleming, 1996) and India (2009) (Kar et al., 2013) and were linked to HFMD. It co-186 
circulated with EV71 in 1998 during the unprecedented HFMD epidemic in Taiwan 187 
(Ho et al., 1999a) and continued circulating in Taiwan becoming dominant in years 188 
2002 and 2003 (Chang, 2008). The co-circulation of CVA16 and EV71 was 189 
documented during HFMD outbreaks in Vietnam in 2005 (Tu et al., 2007) and in 190 
China in 2008 onwards (Liu, 2014). In Singapore CVA16 was the major cause of 191 
HFMD epidemics in years 2002, 2005 and 2007, whereas in 2006 it was EV71 (Ang 192 
et al., 2009).  193 
Co-circulation of EV71 and CVA16 allows viral co-infections (He et al., 2013) 194 
and recombination, which happened during the HFMD outbreak in China (Zhang et 195 
al., 2010a). Recombination between EV71 and CVA16 and accumulation of point 196 
mutations can give rise to viruses with altered antigenicity, thus limiting population 197 
protection and complicating control of viral spread. Both EV71 and CVA16 require 198 
attention as clinically important pathogens. 199 
 200 
Enterovirus 68  201 
Enterovirus 68 belongs to the D species of the Enterovirus genus. Although 202 
genetically it is an enterovirus, EV68 shares properties of both entero- and 203 
rhinoviruses and in most cases causes respiratory infections (Oberste et al., 2004). It 204 
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was first isolated in 1962, but only 26 cases were reported until 2005 and EV68 205 
received little attention from clinical and scientific communities (Khetsuriani et al., 206 
2006). This changed in 2008–2010 when several outbreaks of acute respiratory illness 207 
caused by EV68 were reported by the Centers for Disease Control and Prevention 208 
(CDC) in the Philippines, Japan, the Netherlands and the USA (Imamura et al., 2011). 209 
The affected individuals typically presented with URTI symptoms—cough, fever, 210 
rhinnorea, difficulties in breathing and hypoxia—although severe lower respiratory 211 
tract infections (LRTI) were also detected (Khetsuriani et al., 2006). Individuals 212 
infected with EV68 often required hospitalization: for example, prospective study in 213 
the Netherlands reported that out of 24 EV68-positive subjects, 23 were hospitalized 214 
(Imamura et al., 2011). Deaths were reported in the Philippines and in Japan, but not 215 
in the US and the Netherlands (Imamura et al., 2011). In all studies EV68 was 216 
reported as a paediatric pathogen, except for the work done by Meijer et al. who 217 
reported a significant number of patients over 50 years old (Meijer et al., 2014).  218 
Following the initial outbreaks, EV68 continued its seasonal circulation, and 219 
was occasionally detected in respiratory samples from paediatric patients with URTI 220 
and severe LRTI in different countries, further supporting its clinical relevance and 221 
place as a concern for medical society (Esposito et al., 2015; Gimferrer et al., 2015; 222 
Imamura et al., 2013; Lu et al., 2014). The concern has been raised further after the 223 
EV68 outbreak in the USA in 2014 (Khan, 2015) when over one thousand patients 224 
from 47 states have been diagnosed with acute respiratory illness (ARI) caused by 225 
EV68. The outbreak resulted in a significant increase in hospital admissions: in 226 
Kansas City alone over 300 patients were hospitalized, of which 15% were admitted 227 
to ICU and 15 cases were fatal. Simultaneously, an increased incidence of EV68 ARI 228 
was reported in Canada, where over 200 cases have been identified, resulting in 140 229 
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hospitalizations and one death (Khan, 2015). In 2016 EV68 was detected in patients 230 
with neurological manifestations in the Netherlands, France, UK, Italy, Portugal and 231 
Germany (ECDC, 2016). 232 
Intriguingly, the 2014 EV68 outbreak in North America overlapped with an 233 
outbreak of a polio-like disease with the brain stem and the spinal cord grey matter 234 
lesions and AFP. Infection with EV68 was confirmed in 5 out of 11 (45%) of the 235 
American AFP patients (Messacar et al., 2015). Furthermore, EV68 has been also 236 
detected in four cases of AFP in Canada, two in Norway and one in France (Khan, 237 
2015; Lang et al., 2014; Pfeiffer et al., 2015). A recent retrospective study identified 238 
EV68 in respiratory secretions from 12 of 25 (48%) patients with sporadic paralysis, 239 
strengthening the EV68 link to CNS disease (Greninger et al., 2015). Interestingly, all 240 
the EV68 strains identified in association with paralytic disease formed a distinct 241 
genetic cluster suggesting ongoing emergence and adaptation of this virus (Du et al., 242 
2015). Direct linkage of EV68 to neurological disease has been complicated by 243 
difficulties to detect EV68 or its RNA in patients’ CSF and so far only two studies 244 
succeeded to detect EV68 in patients’ CSF (Khetsuriani et al., 2006; Kreuter et al., 245 
2011). However, we should note that other neurological picornaviruses—PV and 246 
EV71—are also rarely recovered from the CSF, and therefore neurological 247 
involvement of EV68 cannot be ruled out on the basis of negative CSF samples.  248 
The incidence of EV68 has clearly increased over the last decade. Although 249 
this observation could be related to significant improvements in the detection 250 
techniques, the accumulating clinical data suggests that EV68 should be considered 251 
an emerging pathogen. The concerns raised by respiratory EV68 infections and 252 
especially by their possible link to AFP necessitate careful surveillance of the virus 253 
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spread, detailed studies of its pathogenesis and evolution and development of 254 
preventative and/or treatment options. 255 
 256 
Human parechovirus 3 257 
Human parechovirus 3 belongs to species A within genus Parechovirus and is 258 
the second most common human parechovirus (Wolthers et al., 2008). HPeV3 was 259 
isolated in 1999 from an infant with severe CNS disease (Ito et al., 2004),  and since 260 
then it has been recognized as the most or second most prevalent virus causing CNS 261 
infections in infants under 3 months old (Harvala et al., 2009, 2011; Piralla et al., 262 
2014; van der Sanden et al., 2008). Outbreaks of HPeV3 usually occur in summer-263 
autumn seasons and have a distinct biennial pattern (Harvala et al., 2011; Wolthers et 264 
al., 2008). They have been documented in Europe (Benschop et al., 2006), North 265 
America (Boivin et al., 2005), Asia (Yamamoto et al., 2009), and Australia 266 
(Cumming et al., 2015) and are regularly associated with a variety of clinical 267 
presentations, from mild gastrointestinal or respiratory illness to life-threatening 268 
conditions in neonates (Esposito et al., 2014; Harvala et al., 2011; Tapia et al., 2008). 269 
It can cause systemic infections with possible neurological involvement in infants that 270 
are collectively described as “sepsis-like illnesses” (Benschop et al., 2006; 271 
Selvarangan et al., 2011; Wolthers et al., 2008). Such illnesses typically present with 272 
fever, seizures, irritability, respiratory and gastrointestinal problems and occasional 273 
rash being indistinguishable from severe EV infections (Shoji et al., 2013; Verboon-274 
Maciolek et al., 2008). The fraction of symptomatic HPeV3-infected infants that 275 
develop sepsis-like illness can exceed 80%; most of such patients require 276 
hospitalization and up to one third of them are admitted to the ICU (Schuffenecker et 277 
al., 2012; Selvarangan et al., 2011; Shoji et al., 2013).  The CNS symptoms of 278 
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HPeV3 infection can include meningitis, meningoencephalitis, encephalitis or 279 
cerebral hemorrhage with occasional white matter alterations (Khatami et al., 2015; 280 
Kurz et al., 2015).  Whereas HPeV3 meningitis typically has good prognosis, 281 
meningoencephalitis entailing white matter alterations may have long-term sequelae 282 
such as cerebral palsy, learning disabilities, epilepsy or visual impairment (Verboon-283 
Maciolek et al., 2008). In addition, HPeV3 is occasionally associated with 284 
hemophagocytic lymphohistiocytosis (Aviner et al., 2014) and sudden death 285 
syndrome in infants (Schuffenecker et al., 2012). Furthermore, in Japan it was linked 286 
to myositis in children and epidemic myalgia in adults (Mizuta et al., 2013; 287 
Yamamoto et al., 2015).  Fatal cases of HPeV3 infections are known: they resulted 288 
from encephalitis in the absence of an immune response and sometimes also involved 289 
white matter necrosis (Bissel et al., 2015; van Zwol et al., 2009).  290 
Overall, HPeV3 represents a significant threat to neonatal health care. The 291 
incidence of HPeV3 infections and number of CNS disease cases increases (Harvala 292 
et al., 2011) with no treatment options available necessitating search for antivirals and 293 
understanding of HPeV neutralization by antibodies (Wildenbeest et al., 2010). 294 
 295 
NEUTRALIZING ANTIBODIES IN PICORNAVIRUS INFECTIONS 296 
Like with other viruses, the severity and outcome of picornavirus infections depends 297 
both on the viral and host factors.  Host immune status is a key regulator of infection, 298 
and failure to mount an appropriate response inevitably leads to severe disease. The 299 
viral infection is detected by the specific pattern recognition receptors of the innate 300 
immunity that establish a complex signalling network, triggering the expression of 301 
antiviral genes in infected cells and the activation of specific adaptive responses 302 
(Dotzauer & Kraemer, 2012). The adaptive responses rely on the specific populations 303 
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of T-cells and antibody-producing B-cells. Although both innate and cellular adaptive 304 
immunity are essential, a large body of evidence indicates that efficient production of 305 
specific antibodies by the B-cells is primary for the control of picornaviral infections. 306 
Picornaviruses typically infect children, likely due to their naive immune 307 
system. Severe picornavirus infections in healthy adults are uncommon. However, 308 
immunocompromised adults, in particular those with impaired B-cell responses, are 309 
susceptible to prolonged and/or severe picornavirus infections. For example, patients 310 
with X-linked agammaglobulinemina (XLA) have markedly reduced levels of B-cells 311 
and serum antibodies and are susceptible to enterovirus infections (Halliday et al., 312 
2003) with  severe neurological manifestations (Quartier et al., 2000). Moreover, 313 
patients with a- or hypogammaglobulinemia can also develop chronic HPeV1 314 
infection (van de Ven et al., 2011), as well as HPeV3 myocarditis and encephalitis 315 
that are extremely uncommon in adults (Mardekian et al., 2015). Individuals 316 
undergoing immunosuppressive therapy further support the critical role of antibody 317 
responses in the control of picornaviruses. For instance, cancer treatment with 318 
rituximab leads to prolonged B-cell deficiency and hypogammaglobulinemia and 319 
patients receiving such therapy are susceptible to severe and even lethal enterovirus 320 
infections (Servais et al., 2010).  321 
Direct confirmation for the role of antibodies in picornavirus infections comes 322 
from controlled infections in animal models. Experimental infections in mice with 323 
different immunodeficiencies proved the significance of adaptive responses: whereas 324 
up to 70% of mice deficient in innate immune responses survived EV71 infection, 325 
mice with severe combined immunodeficiency developed limb paralysis and died in 326 
almost 100% of cases (Liao et al., 2014). In Theiler’s encephalomyelitis virus 327 
(TMEV)-infected mice—a common model for neurotropic picornaviruses—328 
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immunosuppression with anti-IgM antibodies led to virus-induced demyelinization 329 
(Rodriguez et al., 1990).  330 
At the moment there are no antivirals for treatment of severe picornavirus 331 
infections (Linden et al., 2015; Wildenbeest et al., 2010) and the only therapeutic 332 
option is intravenous immunoglobulin (IVIG). However, because of the low BBB 333 
permeability to antibodies, IVIG is rarely effective in CNS infections although 334 
intraventricular immmunoglobulin administration may be beneficial (Quartier et al., 335 
2000). Antibodies can also be effective at mucosal sites and prevent picornavirus 336 
viremia and CNS invasion (Nathanson & Bodian, 1962). Successful management of 337 
severe picornavirus infections using IVIG (Wildenbeest et al., 2013) indicates the 338 
potential efficacy of passive immunization to control picornavirus infections. 339 
However, the presence of specific neutralizing antibodies and their titres cannot be 340 
controlled in IVIG preparation, and the reliable options of passive immunization 341 
against picornaviruses should be based on the production of specific neutralizing or 342 
broadly neutralizing antibodies that target known viral epitopes. Production of 343 
specific antibodies could also contribute to rapid and specific serology-based 344 
diagnostics of picornavirus infections that are beneficial at time-critical point-of-care 345 
setups. In addition to passive immunization, the success of the polio vaccine 346 
encourages development of vaccines against other picornaviruses. Controlling 347 
picornavirus infections with vaccines is not a feasible approach for the entire 348 
Picornaviridae family, but can be realistic for some virus types. Both vaccine and 349 
antibody development require thorough understanding of viral neutralization, and 350 
below we summarize the current knowledge of the neutralization of CNS-invading 351 
picornaviruses. 352 
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NEUTRALIZATION OF PICORNAVIRUSES 353 
Neutralization of EV71 and CVA16  354 
EV71 is genetically diverse and contains 14 genotypes: A, B1–B5, C1–C5, D, E, and 355 
F (Bessaud et al., 2014); C4 is further classified into two lineages C4a and C4b 356 
(Zhang et al., 2010a). Genotypes B3, B4, B5, C1, C2, C4 and C5 contributed to recent 357 
outbreaks (Chong et al., 2015). CVA16 is less genetically diverse showing relatively 358 
slower evolutionary rate and has 3 genotypes: A, B1 (B1a, B1b, B1c) and B2 (Zhang 359 
et al., 2010b). EV71 can undergo intra- and intergenotype shifts that occur due to 360 
recombination events during co-circulation with CVA16 or different EV71 genotypes 361 
and correlate with most outbreaks (Bible et al., 2007). An effective vaccine should 362 
neutralize multiple serotypes of EV71 and also CVA16. This necessity underpins 363 
difficulties in EV71 vaccine development.  364 
 The first live-attenuated vaccine strain was reported by Arita et al. in 2005. It 365 
induced broadly-neutralizing responses in immunized monkeys, but was neurotropic 366 
when inoculated intravenously and its further development was halted (Arita et al., 367 
2007). Development of inactivated vaccines was more successful: five such vaccines 368 
developed by different organizations entered clinical trials and three of them have 369 
already completed Phase III showing 80.4–97.4% efficacy against EV71-induced 370 
HFMD in humans (Liu et al., 2015a). Two C4-based vaccines developed by the 371 
Chinese Academy for Medical Sciences (CAMS) and Sinovac Biotech Co Ltd were 372 
approved by the Chinese Food and Drug Administration (CFDA) as of January 2016 373 
(Mao et al., 2016). In addition to live-attenuated and inactivated vaccines, virus-like 374 
particle (VLP) vaccine candidates were generated in baculovirus or Saccharomyces 375 
cerevisiae systems using co-expression of viral protein precursor P1 with viral 376 
protease 3CD (Chung et al., 2008; Li et al., 2013). The VLP vaccine candidate 377 
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produced in baculovirus system showed promise in in vivo studies: the survival rate of 378 
VLP-immunized mouse pups after lethal EV71 challenge was superior to those 379 
immunized with inactivated virus (Chung et al., 2008) and it also induced protective 380 
responses in monkeys (Lin et al., 2012). The approved inactivated vaccines cross-381 
protected against B1, B5 and C4a (CAMS vaccine) (Chou et al., 2013) and B4, B5, 382 
C2 and C5 (Sinovac vaccine) (Mao et al., 2013); VLP vaccines protected monkeys 383 
against B4, B5, C3, C4 and C5 (Lin et al., 2012), but none of them neutralized 384 
CVA16. 385 
Multivalent vaccines may offer protection against EV71 and co-circulating 386 
CVA. Bivalent EV71/CVA16 vaccines based on inactivated viruses or VLP can elicit 387 
high titres of neutralizing antibodies in immunized mice and protect from EV71 and 388 
CVA16 infections (Ku et al., 2014). Yet broader protection is desired to mitigate 389 
other HFMD contributors, such as coxsackievirus A6 (CVA6) (Liu et al., 2014), and 390 
one trivalent EV71/CVA16/CVA6 inactivated vaccine candidate protecting mice 391 
from lethal challenge with these viruses was reported (Caine et al., 2015).  392 
Peptide vaccines consisting of well-defined neutralizing epitopes represent a 393 
promising approach to target against several heterologous viruses (Li et al., 2014a). 394 
They are easier to produce compared to inactivated virus vaccines, do not require 395 
handling live virus and allow immunization with lower protein load. Neutralizing 396 
epitopes on EV71 are localized on viral structural proteins VP1, VP2 and VP3 (Fig. 3 397 
(a) and (b)). Three continuous neutralizing epitopes have been localized to VP1 398 
residues 163–177 (known as SP55) and 215–219 (part of SP70 which localizes to 399 
residues 208–222) and to region 240–260 (Chang et al., 2010; Foo et al., 2007; Lim et 400 
al., 2012). SP55 has 85–100% sequence identity within A–C4 groups (Foo et al., 401 
2007) and SP70 is 100% conserved across EV71 genotypes A–C4 and thus is 402 
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universal for them. In addition, VP1 encompasses a strain-specific discontinuous 403 
neutralization epitope at the 5-fold symmetry axis with residue 145 critically 404 
contributing to antibody interaction (Lee et al., 2013). Two other neutralizing 405 
epitopes were localized to residues 136–150 of VP2 (known as VP2-28) (Liu et al., 406 
2011), and to VP3 residues 55–69 that form a “knob” and are 100% conserved across 407 
EV71 subgenogroups A-C4  (Kiener et al., 2014). Much less is known about 408 
neutralizing epitopes in CVA16. Most of the experimentally proven neutralizing 409 
epitopes of CVA16 were localized to VP1 (GH, EF, C-terminal loops and B and C β-410 
sheets) (Ren et al., 2015; Shi et al., 2013); one more continuous epitope was found in 411 
GH loop of VP3 (Chong et al., 2012) (Fig 3 (b)). Additional antigenic sites of CVA16 412 
were predicted in silico in EF and HI loops of VP2 (Ren et al., 2015). Although 413 
peptide vaccines are usually less immunogenic compared to the viral particles, this 414 
can be mitigated using adjuvants or fusing viral epitopes with highly immunogenic 415 
antigens. Using such an approach, a tandem of three well described EV71 epitopes—416 
SP55, SP70 and VP2-28—separated by Gly-Ser linker and fused to thioredoxin was 417 
expressed in E. coli.  The recombinant protein induced EV71-specific neutralizing 418 
responses in immunized mice, serving as a proof-of-concept for peptide vaccines 419 
against HFMD (Li et al., 2014b). In another study, a hepatitis B virus-like particle 420 
displaying EV71 SP55 and VP2-28 epitopes induced neutralizing responses in 421 
immunized mice, and could also be cross-protective against CVA16 (Xu et al., 422 
2015b). In terms of immunogenicity EV71 is one of the best-studied picornaviruses 423 
with two EV71 vaccines approved by CFDA and further work will be driven by the 424 
necessity of multivalent HFMD vaccines.  425 
 426 
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Neutralization of enterovirus 68 427 
EV68 is an emerging virus and little is known about its antigenicity. Imamura et al. 428 
studied the immunogenic properties of twelve EV68 genotypes belonging to all three 429 
genetic lineages of EV68—A, B and C (Imamura et al., 2013). Immunized guinea 430 
pigs generated high titres of neutralizing antibodies to the original virus and to viruses 431 
of the same lineage, but very little cross-neutralization between genetic lineages was 432 
found (Imamura et al., 2014). Importantly, the majority of sequence variation between 433 
EV68 lineages is localized to the VP1 BC and DE surface loops (Imamura et al., 434 
2013, 2014; Liu et al., 2015b), which are the most variable and likely are epitope-435 
containing in enteroviruses. Indeed, VP1 likely contains antigenic determinants as the 436 
increase in its gene diversity correlates with an increase in the number of EV68 437 
detections (Meijer et al., 2012), reflecting the appearance of antigenically new viruses 438 
in the population. Substitution dynamics within the viral genome also suggests the 439 
localization of antigenic epitopes to VP1: several positions in VP1 BC and DE loops 440 
(Fig. 3 (b)) are undergoing positive selection and might be associated with antigenic 441 
differences between EV68 genetic lineages (Imamura et al., 2014). Nevertheless, to 442 
date the exact immunogenic epitopes of EV68 are only predictive and have not been 443 
mapped.  444 
Not much is also known about the distribution of EV68 neutralizing antibodies 445 
in human population. One study done in Finland addressed this question reporting 446 
high titres of neutralizing responses to EV68 in 80% of the studied individuals (Smura 447 
et al., 2010). However, neutralization responses in this study were addressed against 448 
the prototype EV68 Fermon strain, which is antigenically very different from the 449 
currently circulating EV68 strains (Greninger et al., 2015; Meijer et al., 2012). 450 
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Therefore, neither EV68 antigenicity, nor the population protection levels are 451 
understood well at the moment.   452 
 453 
Neutralization of HPeV3 454 
 455 
Almost nothing is known about HPeV3 antigenicity.  Of the parechoviruses, only 456 
antigenicity of HPeV1 has been studied (Shakeel et al., 2015) and so far three 457 
neutralizing epitopes on HPeV1 structural proteins VP0, VP1 and VP3 are described. 458 
One is localized to residues 83-97 of VP0 (Joki-Korpela et al., 2000), another is found 459 
on VP1 and encompasses receptor recognizing arginine-glycine-aspartic acid (RGD) 460 
motif (Alho et al., 2003) and the third one is formed by VP0 and VP3 (Shakeel et al., 461 
2015; Westerhuis et al., 2015). Whereas antisera generated against HPeV1 VP0 462 
peptide was not tested for HPeV3 neutralization, two other monoclonal antibodies did 463 
not cross-react with HPeV3 (Shakeel et al., 2015; Westerhuis et al., 2015). For 464 
HPeV3 only non-neutralizing epitope has been described (Shakeel et al., 2016) 465 
 The data on HPeV3 seroprevalence in population is also sparse. A study of 466 
sera from populations in Finland and Netherlands revealed neutralizing responses to 467 
HPeV3 only in about 10% of the samples and very low titres of neutralizing 468 
antibodies post infection (Westerhuis et al., 2013). On the contrary, researchers in 469 
Japan detected neutralizing responses to HPeV3 in 67% of individuals between 7 470 
months and 40 years old (Ito et al., 2004), and reported high titres of neutralizing 471 
antibodies after 3 months post infection in all studied individuals (Aizawa et al., 472 
2015). The virus strains used in European and Japanese studies were different, 473 
suggesting that some strains of HPeV3 are strongly immunogenic, whereas others are 474 
not. The determinants of immunogenicity within this virus are currently unknown and 475 
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investigation of the Japanese A308/99 strain immunogenicity may shed light on the 476 
neutralization of HPeV3.  477 
The treatment option for human parechovirus infections could be IVIG 478 
(Wildenbeest et al., 2013), but titres of neutralizing antibodies against HPeV3 in 479 
European IVIG preparations are very low (Westerhuis et al., 2012). Developing 480 
vaccines does not seem feasible because subjects of severe HPeV3 infections are 481 
infants. Passive immunization protects against HPeV3 (Aizawa et al., 2015) thus 482 
developing therapeutic antibodies is a necessity for which studies of HPeV3 483 
antigenicity are required.  484 
 485 
CONCLUSIONS AND FUTURE PERSPECTIVES 486 
Our understanding of antigenicity of picornaviruses that target CNS is very poor and 487 
is largely limited to studies of EV71. Although studies of EV71 have already resulted 488 
in two CFDA-approved HFMD vaccines, multivalent HFMD vaccines to control 489 
different EV71 genotypes and also co-circulating CVA16 are the next goal. Proof-of-490 
concept studies of such vaccines are promising (Caine et al., 2015; Sun et al., 2014), 491 
but further work is needed to identify the optimal combination of antigens for 492 
balanced, broadly protective immunity. Targeting multiple viruses with a single shot 493 
also requires delivery systems for effective presentation of multiple epitopes. In this 494 
regard, VLP and peptide vaccines may be preferable over inactivated vaccines, 495 
offering tailored solutions in terms of presented antigens together with comparable 496 
immunogenicity, high safety and less tedious production, and economical feasibility 497 
(Li et al., 2014a).    498 
We know almost nothing about EV68 and HPeV3 antigenicity. Classical 499 
approach to study virus antigenicity and develop vaccines relies on animal models, 500 
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which is just being developed for EV68 and not available for HPeV3, hampering 501 
investigation of these viruses. Therefore, their antigenicity should be studied directly 502 
from human sera using novel methods, such as peptide arrays (Hansen et al., 2013), 503 
classical phage display  or phage display enhanced with next generation sequencing 504 
(NGS) (Christiansen et al., 2015).  Successful use of custom phage display library and 505 
NGS was reported by Xu et al. who analysed antibody-peptide interactions in sera of 506 
over 550 donors and identified numerous previously undescribed viral epitopes, 507 
proving the utility of NGS-enhanced phage display for epitope identification (Xu et 508 
al., 2015a).  509 
 Another future direction is the search for EV68 and HPeV3 neutralizing 510 
antibodies. In the absence of antivirals (Linden et al., 2015; Wildenbeest et al., 2010), 511 
such antibodies could be valuable therapeutics, especially for HPeV3 that infects 512 
infants for whom vaccination is not a suitable option. A useful approach for that is 513 
identification of individual’s immune response to a given virus followed by respective 514 
B-cell cloning (Kwakkenbos et al., 2014). This approach was utilized to generate two 515 
broadly neutralizing antibodies against HPeV (Shakeel et al., 2015; Westerhuis et al., 516 
2015). Unfortunately, these antibodies did not neutralize HPeV3. High throughput 517 
approaches, such as sequencing of antibody repertoire (Georgiou et al., 2014) and 518 
screening of large antibody fragments libraries using ribosomal, bacterial, yeast or 519 
phage display (Bradbury et al., 2011) are also utilized for antibody discovery. For 520 
instance, phage display technology has already yielded monoclonal neutralizing 521 
antibodies with therapeutic potential for EV71 (Zhang et al., 2015). Over 50 phage-522 
display derived antibodies have been approved by the U.S.  Food and Drug 523 
Administration (FDA) or European Medicines Agency (EMA) as of May, 2016. 524 
About 500 antibodies are undergoing clinical trials. These include antibodies targeting 525 
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infectious agents, for example Rabies virus, which is now in Phase II (Frenzel et al., 526 
2016). 527 
  Overall, picornaviruses antigenicity and neutralization studies have already 528 
brought encouraging results, however more challenges are ahead. The detailed 529 
understanding of viral immunogenicity is clearly an important task to focus on, but it 530 
should be carried out in parallel with broader studies of viral biology and spread. 531 
Although many research groups in Europe, US and Asia are very active in the field of 532 
picornavirus research, we are still far from a thorough understanding of viral 533 
epidemiology, pathogenesis, evolution and inhibition, which are necessary for 534 
effective virus control. Apart from scientific challenges, development protective 535 
measures against picornaviruses may face additional financial and regulatory 536 
difficulties due to the endemic nature of diseases that they cause. Hence, drawing the 537 
public attention to the health care threats that picornaviruses impose is another 538 
important activity area for the medical and scientific communities. 539 
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FIGURE LEGENDS 
Fig. 1. Classification of picornaviruses. The scheme shows picornavirus genera and 
species that infect humans. Clinically important genotypes are also shown. The 
genotypes associated with neurological infections are highlighted with heavy font. 
 
Fig. 2. Routes of picornavirus entry to the CNS. (a) Picornaviruses can infect 
peripheral nerve and invade CNS via retrograde axonal transport. (b) They can and 
spread further in CNS in a trans-synaptic manner. (c) During viremia picornaviruses 
can enter the CNS via hematogenous route through a disintegrated blood-brain 
barrier. (d) They can also cross the blood-brain-barrier in an active manner, possibly 
relying on cellular transferrin receptor 1. (e) Picornaviruses can infect migrating cells 
and invade CNS in a “Trojan horse” manner.  
 
Fig. 3.  Enterovirus structure and localization of immunogenic epitopes on viral 
surface. (a) Icosahedral picornavirus capsid, shown for EV71 (PDB ID: 3VBS), 
consists of 60 identical structural units (asymmetric units). Each asymmetric unit is 
composed of four viral structural proteins: VP1 (dark green), VP2 (grey), VP3 (light 
green) and VP4 (attached to the inner surface of the capsid and not seen in the 
cartoon). (b) Localization of known immunogenic epitopes on EV71 (PDB ID: 
3VBS) (upper panel), CVA16 (PDB ID: 5C4W) (middle panel) and predicted 
epitope-containing loops on EV68 (PDB ID: 4WM8) (lower panel). For simplicity, 
only one structural unit is mapped on each virus. Structural proteins VP1 (dark green), 
VP2 (grey) and VP3 (light green) are shown. The epitopes are marked in orange and 
are pointed with arrows on a zoomed image. Overlapping epitopes are marked in red. 
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